<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542603</url>
  </required_header>
  <id_info>
    <org_study_id>R20-100</org_study_id>
    <nct_id>NCT04542603</nct_id>
  </id_info>
  <brief_title>Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer</brief_title>
  <official_title>Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will use the small molecule translocator protein (TSPO) ligand,&#xD;
      18F-labeled DPA- 714, to visualize and quantify neuroinflammation in treatment naivete women&#xD;
      with stage 1-4 newly diagnosed ovarian cancer (without brain metastases) prior to starting&#xD;
      neoadjuvant chemotherapy treatment (baseline) and within a month of completing first 6 cycles&#xD;
      of cytotoxic chemotherapy treatment (follow-up). In addition, we will use the&#xD;
      well-characterized small molecule PET(Positron Emission Tomography) tracer, 11C-labeled&#xD;
      Pittsburgh compound B (PiB) to visualize and quantify the regional brain distribution of&#xD;
      pathological amyloid deposition at baseline only. The brain amyloid PET and MRI data acquired&#xD;
      through this study will be correlated with cognitive test data, clinical data, genetic&#xD;
      testing, and biospecimens collected in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure neuroinflammation by calculating the concentration and regional distribution of activated brain microglia/macrophages using the PET ligand [F-18]DPA-714.</measure>
    <time_frame>Pre-study visit through 3-6 cycles of chemotherapy (each cycle is typically 2 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate cognitive impairment before and after beginning cancer therapy with the concentration and regional brain distribution of pathologic amyloid deposition measured with the PET tracer [C-11]PiB prior to beginning therapy.</measure>
    <time_frame>Pre-study visit through 3-6 cycles of chemotherapy (each cycle is typically 2 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>treatment naivete women with stage 1-4 newly diagnosed ovarian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]PiB and 18F-labeled DPA-714 PET scan</intervention_name>
    <description>One PET with [11C]PiB and One PET with [18F]DPA-714 before chemotherapy treatment begins. One more PET with [18F]DPA-714 after completion of 3-6 cycles of chemotherapy.</description>
    <arm_group_label>treatment naivete women with stage 1-4 newly diagnosed ovarian</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 50 years of age or older&#xD;
&#xD;
          2. Female gender&#xD;
&#xD;
          3. Newly diagnosed treatment na√Øve women with stage III/IV epithelial ovarian cancer&#xD;
             (without known brain metastases).&#xD;
&#xD;
          4. High or mixed affinity binder for TSPO ligands based on genotyping for single&#xD;
             nucleotide polymorphism (SNP) rs6971.&#xD;
&#xD;
          5. English is primary language&#xD;
&#xD;
          6. Planned neoadjuvant chemotherapy with platinum and taxane drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to MRI&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Lactation&#xD;
&#xD;
          4. Individuals who are unable to participate in the imaging portion due to severity of&#xD;
             their medical condition&#xD;
&#xD;
          5. Chronic infectious disease (e.g. HIV, HCV)&#xD;
&#xD;
          6. Chronic inflammatory disease (e.g., fibromyalgia, MS, etc) or autoimmune disease&#xD;
&#xD;
          7. Viral or bacterial illness requiring medical attention and/or antibiotics within 1&#xD;
             month of study participation&#xD;
&#xD;
          8. Blood or blood clotting disorder&#xD;
&#xD;
          9. Cancer that has metastasized to the brain&#xD;
&#xD;
         10. Positive urine hCG test day of procedure or a serum hCG test within 48 hours prior to&#xD;
             the administration of [18F]DPA-714 and [11C]PiB.&#xD;
&#xD;
         11. Currently enrolled in a clinical trial utilizing experimental therapies.&#xD;
&#xD;
         12. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.&#xD;
&#xD;
         13. Prior brain tumor or other neurological condition known to affect cognition&#xD;
&#xD;
         14. A diagnosis of dementia unrelated to cancer or an adjusted MMSE score &lt; 24&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BS RT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>April Riddle, BS RT</last_name>
      <phone>205-934-6504</phone>
      <email>ariddle@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>For, BS</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jonathan McConathy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerri Bevis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pradeep Bhambhvani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gagandeep Choudhary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Warner Huh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Denise Jeffers, RPh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne Lapi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Leath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Liang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>L. Burt Nabors, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Straughn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristen Tribel (Gerstenecker), PsyD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>M.D. P.h.D., Director for the Division Molecular Imaging and Therapeutics Affiliation: University of Alabama at Birmingham Collaborators:</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

